CN113100439A - NMN formula product for prolonging chromosome telomere and preparation method thereof - Google Patents
NMN formula product for prolonging chromosome telomere and preparation method thereof Download PDFInfo
- Publication number
- CN113100439A CN113100439A CN202110536156.1A CN202110536156A CN113100439A CN 113100439 A CN113100439 A CN 113100439A CN 202110536156 A CN202110536156 A CN 202110536156A CN 113100439 A CN113100439 A CN 113100439A
- Authority
- CN
- China
- Prior art keywords
- parts
- nmn
- powder
- weight
- telomeres
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000003411 telomere Anatomy 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title abstract description 8
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract description 72
- 239000000843 powder Substances 0.000 claims abstract description 72
- 239000000463 material Substances 0.000 claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 16
- 235000003392 Curcuma domestica Nutrition 0.000 claims abstract description 16
- 241000168517 Haematococcus lacustris Species 0.000 claims abstract description 16
- 244000131360 Morinda citrifolia Species 0.000 claims abstract description 16
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000220317 Rosa Species 0.000 claims abstract description 16
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 16
- 240000000851 Vaccinium corymbosum Species 0.000 claims abstract description 16
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims abstract description 16
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims abstract description 16
- 235000019206 astragalus extract Nutrition 0.000 claims abstract description 16
- 235000021014 blueberries Nutrition 0.000 claims abstract description 16
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 16
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 16
- 235000013557 nattō Nutrition 0.000 claims abstract description 16
- 235000017524 noni Nutrition 0.000 claims abstract description 16
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 16
- 229940016667 resveratrol Drugs 0.000 claims abstract description 16
- 235000013976 turmeric Nutrition 0.000 claims abstract description 16
- 239000000047 product Substances 0.000 claims description 46
- 108091035539 telomere Proteins 0.000 claims description 20
- 102000055501 telomere Human genes 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 17
- 238000009472 formulation Methods 0.000 claims description 15
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 14
- 229920002498 Beta-glucan Polymers 0.000 claims description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 14
- 235000013325 dietary fiber Nutrition 0.000 claims description 14
- 210000000349 chromosome Anatomy 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 229960001109 policosanol Drugs 0.000 claims description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 235000013373 food additive Nutrition 0.000 claims 3
- 239000002778 food additive Substances 0.000 claims 3
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 7
- 230000009758 senescence Effects 0.000 abstract description 3
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 230000005778 DNA damage Effects 0.000 description 3
- 231100000277 DNA damage Toxicity 0.000 description 3
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 3
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 102000011990 Sirtuin Human genes 0.000 description 3
- 108050002485 Sirtuin Proteins 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000032677 cell aging Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 230000008265 DNA repair mechanism Effects 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/13—Nucleic acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an NMN formula product for prolonging chromosome telomeres, wherein a unit product comprises the following components: 300 parts of beta-NMN 150, 25-35 parts of resveratrol, 10-50 parts of astragalus extract, 10-50 parts of centella asiatica extract, 45-75 parts of blueberry powder, 1.5-5.0 parts of haematococcus pluvialis, 30-100 parts of turmeric, 5-10 parts of natto powder, 5-30 parts of polycosanol, 180 parts of noni powder 120, 20-30 parts of roxburgh rose powder and the balance of food auxiliary materials; the total weight of the unit product is 1000 parts by weight. The formula product can effectively prolong chromosome telomeres and delay cell senescence. The unit preparation cost of the formula product is reduced.
Description
Technical Field
The invention relates to the technical field of health-care food, in particular to an NMN formula product for prolonging chromosome telomeres and a preparation method thereof.
Background
There is a concept of "Hayflick Limit" in medicine, proposed in 1965 by the American microbiologist Leonard Hayflick, which indicates that human cells die by themselves after 50-60 divisions. Clinical medicine tends to identify this as the cause of our body aging and death, i.e. human cells divide themselves 50-60 times to maintain the limit of the body's metabolic cycle. The key factor causing the limit is that chromosome telomeres have certain length limit, the chromosome telomeres are partially lost when cells are divided once, and the cells die after the telomeres are completely lost.
The cell naturally has a mechanism for delaying the shortening of chromosome telomeres, namely DNA repair mechanisms of NAD + -dependent PARPs and Sirtuins. However, with age, intracellular CD38 activity surges, consuming large amounts of NAD +, resulting in loss of PARPs from the fuel required to repair DNA damage; the longevity proteins Sirtuins also lose their longevity function due to the lack of NAD + availability. As the activity of CD38 rises rapidly, firstly, the sudden reduction of NAD + level and the reduction of Sirtuins activity directly cause the abnormity of mitochondrial function, and generate a large amount of Reactive Oxygen Species (ROS) in vivo while seriously disturbing energy metabolism, thereby causing serious damage to biomacromolecules such as DNA and the like; subsequently, the insufficient activity of PARPs makes DNA damage unable to be repaired, and the structure of telomere "TTAGGG" is additionally easy to be a target of active oxygen, telomere shortening and DNA damage rate are further increased, genome stability is suddenly reduced, and the whole cell is forced to be in an aging state in a very short time. NMN is used as a precursor of NAD +, and the supplement of NMN can quickly recover mitochondrial problems caused by excessively short telomeres through a salvage synthesis way; after the mitochondrial function is repaired, active oxygen is greatly reduced, and the shortening speed of telomeres in cells is directly delayed, namely NMN can delay cell aging.
However, when the NMN is taken from food, the NMN intake required by human body every day is difficult to obtain. Existing NMN-containing products are: health food, medicine, cosmetics, etc., but because NMN is expensive, the manufacturing cost of the NMN formula product is high; if the addition amount of the NMN is reduced, the anti-aging effect of the NMN formula product is poor or not obvious.
Disclosure of Invention
The technical problem to be solved by the invention is as follows: an NMN formula product with low production cost and the effect of remarkably prolonging chromosome telomeres is designed.
In order to solve the technical problems, the invention adopts the technical scheme that:
an NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 300 parts of beta-NMN 150, 25-35 parts of resveratrol, 10-50 parts of astragalus extract, 10-50 parts of centella asiatica extract, 45-75 parts of blueberry powder, 1.5-5.0 parts of haematococcus pluvialis, 30-100 parts of turmeric, 5-10 parts of natto powder, 5-30 parts of polycosanol, 180 parts of noni powder 120, 20-30 parts of roxburgh rose powder and the balance of food auxiliary materials; the total weight of the unit product is 1000 parts by weight.
Further, the unit product comprises the following components: 200-250 parts of beta-NMN, 28-32 parts of resveratrol, 25-35 parts of astragalus extract, 20-40 parts of centella asiatica extract, 50-60 parts of blueberry powder, 3.0-4.0 parts of haematococcus pluvialis, 50-80 parts of turmeric, 7-9 parts of natto powder, 15-25 parts of polycosanol, 140-160 parts of noni powder and 24-28 parts of roxburgh rose powder, and the balance being food auxiliary materials.
Further, the unit product comprises the following components: 200 parts of beta-NMN, 30 parts of resveratrol, 32 parts of astragalus extract, 35 parts of centella asiatica extract, 50 parts of blueberry powder, 4.0 parts of haematococcus pluvialis, 60 parts of turmeric, 8 parts of natto powder, 22 parts of polycosanol, 150 parts of noni powder, 25 parts of roxburgh rose powder and the balance of food auxiliary materials.
Further, the food auxiliary material is one or more of yeast beta-glucan, dietary fiber, maltodextrin and starch.
Further, the food auxiliary material comprises 30-70 parts by weight of yeast beta-glucan and 50-100 parts by weight of dietary fiber.
Further, the food auxiliary material comprises 40-50 parts by weight of yeast beta-glucan and 80-100 parts by weight of dietary fiber.
Further, the product is a capsule or powder or tablet or a candy.
A preparation method of an NMN formula product for prolonging chromosome telomeres comprises the steps of mixing beta-NMN, resveratrol, an astragalus extract, a centella asiatica extract, blueberry powder, haematococcus pluvialis, turmeric, natto powder, policosanol, noni powder and roxburgh rose powder according to required proportion to obtain a premixed main material, premixing and stirring the premixed main material, and then adding food auxiliary materials in corresponding proportion.
Further, when the food auxiliary materials are added, the yeast beta-glucan and the dietary fiber in the required proportion are added into the premixed main material, and then the maltodextrin or the starch in the corresponding proportion is added.
Further, in the rotary stirring tank, the raw materials are added while stirring; after all the raw materials are added, continuously rotating and stirring for 20-60min to form a premix; and subpackaging the premix into the product according to different user requirements.
The invention has the beneficial effects that: can effectively prolong chromosome telomeres and delay cell senescence. The unit preparation cost of the formula product is reduced.
Drawings
The detailed structure of the invention is described in detail below with reference to the accompanying drawings
Figure 1 is a graph of relative length of telomeres on chromosomes in mice (16 months of age) dosed with the NMN formulation of the invention or β -NMN alone versus control (.; P < 0.05;. P < 0.01);
FIG. 2 is a graph of a comparison of the relative lengths of chromosome telomeres before and after the age of the elderly (70 + -8 years) taking the NMN formulation of the present invention or β -NMN30 alone (P < 0.05; ns, no significant difference);
fig. 3 is a graph comparing the relative lengths of chromosome telomeres before and after the middle aged (55 ± 3 years) had taken the NMN formulation of the present invention or β -NMN30 days alone (x, P < 0.01; ns, no significant difference);
fig. 4 is a graph comparing the relative lengths of chromosomal telomeres before and after the elderly (70 ± 8 years) took the NMN formulations of examples 1-6 of the present invention or β -NMN30 days alone.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings of the present invention, and it is obvious that the described embodiments are some, not all, embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 200 parts by weight of beta-NMN, 30 parts by weight of resveratrol, 32 parts by weight of astragalus extract, 35 parts by weight of centella asiatica extract, 50 parts by weight of blueberry powder, 4.0 parts by weight of haematococcus pluvialis, 60 parts by weight of turmeric, 8 parts by weight of natto powder, 22 parts by weight of policosanol, 150 parts by weight of noni powder, 25 parts by weight of roxburgh rose powder, 45 parts by weight of yeast beta-glucan, 90 parts by weight of dietary fiber and the balance of starch; the total weight of the unit product is 1000 parts by weight.
Example 2
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 150 parts by weight of beta-NMN, 25 parts by weight of resveratrol, 45 parts by weight of astragalus extract, 35 parts by weight of centella asiatica extract, 45 parts by weight of blueberry powder, 1.5 parts by weight of haematococcus pluvialis, 60 parts by weight of turmeric, 5 parts by weight of natto powder, 5 parts by weight of policosanol, 120 parts by weight of noni powder, 20 parts by weight of roxburgh rose powder, 30 parts by weight of yeast beta-glucan, 50 parts by weight of dietary fiber and the balance of starch; the total weight of the unit product is 1000 parts by weight.
Example 3
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 300 parts by weight of beta-NMN, 35 parts by weight of resveratrol, 25 parts by weight of astragalus extract, 50 parts by weight of centella asiatica extract, 75 parts by weight of blueberry powder, 5.0 parts by weight of haematococcus pluvialis, 30 parts by weight of turmeric, 10 parts by weight of natto powder, 30 parts by weight of policosanol, 120 parts by weight of noni powder, 30 parts by weight of roxburgh rose powder, 70 parts by weight of yeast beta-glucan, 100 parts by weight of dietary fibers and the balance of maltodextrin; the total weight of the unit product is 1000 parts by weight.
Example 4
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 220 parts of beta-NMN, 28 parts of resveratrol, 25 parts of astragalus extract, 20 parts of centella asiatica extract, 50 parts of blueberry powder, 3.0 parts of haematococcus pluvialis, 50 parts of turmeric, 7 parts of natto powder, 15 parts of policosanol, 140 parts of noni powder, 24 parts of roxburgh rose powder, 40 parts of yeast beta-glucan, 80 parts of dietary fiber and the balance of starch; the total weight of the unit product is 1000 parts by weight.
Example 5
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 250 parts by weight of beta-NMN, 32 parts by weight of resveratrol, 35 parts by weight of astragalus extract, 40 parts by weight of centella asiatica extract, 60 parts by weight of blueberry powder, 4.0 parts by weight of haematococcus pluvialis, 80 parts by weight of turmeric, 9 parts by weight of natto powder, 25 parts by weight of policosanol, 160 parts by weight of noni powder, 28 parts by weight of roxburgh rose powder, 50 parts by weight of yeast beta-glucan and 100 parts by weight of dietary fiber, and the balance of starch; the total weight of the unit product is 1000 parts by weight.
Example 6
An NMN formula for prolonging chromosome telomeres, wherein the unit product comprises the following components: 230 parts of beta-NMN, 28 parts of resveratrol, 35 parts of astragalus extract, 30 parts of centella asiatica extract, 60 parts of blueberry powder, 3.0 parts of haematococcus pluvialis, 70 parts of turmeric, 8 parts of natto powder, 25 parts of polycosanol, 140 parts of noni powder, 24 parts of roxburgh rose powder and the balance of starch; the total weight of the unit product is 1000 parts by weight.
Example 7
A preparation method of an NMN formula product for prolonging chromosome telomeres comprises the steps of mixing beta-NMN, resveratrol, astragalus extract, centella asiatica extract, blueberry powder, haematococcus pluvialis, turmeric, natto powder, policosanol, noni fruit powder and roxburgh rose powder in a rotary stirring tank according to required proportion to obtain a premixed main material, premixing and stirring the premixed main material, and then adding food auxiliary materials in corresponding proportion.
Preferably, when the food auxiliary materials are added, the yeast beta-glucan and the dietary fiber in the required proportion are added into the premixed main material, and then the maltodextrin or the starch in the corresponding proportion is added. Adding raw materials while stirring; and after all the raw materials are added, continuously rotating and stirring for 20-60 min.
The product is a capsule or powder or tablet or a candy.
Comparative example 1
An NMN-containing product, comprising the following ingredients in a unit product: 200 parts by weight of beta-NMN and 800 parts by weight of starch.
In order to discuss the beneficial effects of the invention, the powders of comparative example 1 and example 1 are respectively added into the grain of mice to feed the mice to 16 months old, each mouse takes 30mg per day, the mice of a control group only feed the grain of the mice, and each group of the mice only feed 10 mice. After feeding for one month, the relative length of chromosome telomeres of peripheral blood leukocytes of each group of mice is tested by a real-time quantitative PCR method, and the result is detailed in figure 1.
As can be seen from the results in fig. 1, the relative length of telomeres of the β -NMN chromosome taken alone was significantly different from that of the blank control; the relative length of the chromosome telomere of the NMN formula product has extremely obvious difference with a blank control when the NMN formula product is taken; significant differences are also achieved between taking the NMN formula product of the invention and taking beta-NMN alone. Namely, the chromosome telomere of a mouse can be effectively prolonged by singly taking the beta-NMN and the NMN formula product, but the effect of prolonging the chromosome telomere of the NMN formula product is better.
To further discuss the beneficial effects of the present invention, the powders of comparative example 1 and example 1 were administered to elderly (age 70 ± 8 years) and middle aged (age 55 ± 3 years) respectively, 16 persons were administered each day at 1g, and the relative length of human peripheral blood leukocyte chromosome telomere was determined by real-time quantitative PCR method before and 1 month after administration, the determination method is conventional real-time quantitative PCR method, and the test results are shown in fig. 2 and fig. 3.
As can be seen from the results in FIG. 2, the relative length of telomeres of beta-NMN chromosome was extended but not significantly different in elderly (70. + -. 8 years) when taken alone; the relative length of the chromosome telomere is prolonged and the difference is very obvious when the NMN formula product is taken; significant differences are also achieved between taking the NMN formulation of the present invention versus beta-NMN alone.
As can be seen from the results in fig. 3, the relative length of telomeres of β -NMN chromosomes was prolonged but not significantly different in the middle aged and elderly (age 55 ± 3 years) when taken alone; the relative length of the chromosome telomere is prolonged and the difference is very obvious when the NMN formula product is taken; significant differences are also achieved between taking the NMN formulation of the present invention versus beta-NMN alone.
That is, as can be seen from fig. 2 and 3, both β -NMN and the NMN formulation of the present invention are effective in extending chromosome telomeres in the elderly (age 70 ± 8 years) and the elderly (age 55 ± 3 years), but the NMN formulation of the present invention has a better effect in extending chromosome telomeres.
To further illustrate the beneficial effects of the present invention, the powders of examples 2-6 were administered to the elderly (70 + -8 years), 16 persons were administered each day at 1g, and the relative lengths of telomeres of human peripheral blood leukocytes were determined by real-time quantitative PCR method before and after 1 month of administration, and the results are shown in FIG. 4.
As can be seen from fig. 4, the administration of the powders of examples 2 to 6 of the present invention had the effect of significantly prolonging telomeres on chromosomes and delaying senescence, as did the powder of example 1.
In conclusion, compared with the single administration of beta-NMN, the NMN formula product for prolonging the chromosome telomeres provided by the invention can be used for more effectively prolonging the chromosome telomeres and delaying cell aging after being taken, so that the unit preparation cost of the formula product is reduced.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all modifications of equivalent structures and equivalent processes performed by the present specification and drawings, or directly or indirectly applied to other related technical fields, are included in the scope of the present invention.
Claims (10)
1. An NMN formula for lengthening chromosome telomeres, wherein the unit product comprises the following components: 300 parts of beta-NMN 150, 25-35 parts of resveratrol, 10-50 parts of astragalus extract, 10-50 parts of centella asiatica extract, 45-75 parts of blueberry powder, 1.5-5.0 parts of haematococcus pluvialis, 30-100 parts of turmeric, 5-10 parts of natto powder, 5-30 parts of polycosanol, 180 parts of noni powder 120, 20-30 parts of roxburgh rose powder and the balance of food auxiliary materials; the total weight of the unit product is 1000 parts by weight.
2. The NMN formulation for lengthening telomeres in chromosomes according to claim 1, wherein the unit product comprises the following ingredients: 200-250 parts of beta-NMN, 28-32 parts of resveratrol, 25-35 parts of astragalus extract, 20-40 parts of centella asiatica extract, 50-60 parts of blueberry powder, 3.0-4.0 parts of haematococcus pluvialis, 50-80 parts of turmeric, 7-9 parts of natto powder, 15-25 parts of polycosanol, 140-160 parts of noni powder and 24-28 parts of roxburgh rose powder, and the balance being food auxiliary materials.
3. The NMN formulation for lengthening telomeres in chromosomes according to claim 2, wherein the unit product comprises the following ingredients: 200 parts of beta-NMN, 30 parts of resveratrol, 32 parts of astragalus extract, 35 parts of centella asiatica extract, 50 parts of blueberry powder, 4.0 parts of haematococcus pluvialis, 60 parts of turmeric, 8 parts of natto powder, 22 parts of polycosanol, 150 parts of noni powder, 25 parts of roxburgh rose powder and the balance of food auxiliary materials.
4. The NMN formulation for lengthening telomeres in chromosomes according to any of claims 1 to 3, wherein the food additive is one or more of yeast β -glucan, dietary fiber, maltodextrin, and starch.
5. The NMN formulation for lengthening telomeres in chromosomes according to claim 4, wherein the food additive comprises 30 to 70 parts by weight yeast β -glucan and 50 to 100 parts by weight dietary fiber.
6. The NMN formulation for lengthening telomeres in chromosomes according to claim 5, wherein the food additive comprises 40 to 50 parts by weight yeast β -glucan and 80 to 100 parts by weight dietary fiber.
7. The NMN formulation for lengthening telomeres in chromosomes according to claim 6, wherein the product is in the form of a capsule or powder or tablet or candy.
8. The method for preparing NMN formula products for prolonging telomeres of chromosomes according to any one of claims 1 to 7, is characterized in that beta-NMN, resveratrol, astragalus extract, centella asiatica extract, blueberry powder, haematococcus pluvialis, turmeric, natto powder, policosanol, noni powder and roxburgh rose powder are mixed according to required mixture ratio to obtain pre-mixed main materials, and the pre-mixed main materials are pre-mixed and stirred and then added with food auxiliary materials in corresponding mixture ratio.
9. The method of claim 8, wherein the food supplement is added by adding yeast β -glucan and dietary fiber in a desired ratio to the pre-mixed base material and then adding maltodextrin or starch in a corresponding ratio.
10. The method of claim 9, wherein the NMN formulation for extending telomeres in chromosomes is added while stirring in a rotating stirring vessel; after all the raw materials are added, continuously rotating and stirring for 20-60min to form a premix; and subpackaging the premix into the product according to different user requirements.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110536156.1A CN113100439A (en) | 2021-05-17 | 2021-05-17 | NMN formula product for prolonging chromosome telomere and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110536156.1A CN113100439A (en) | 2021-05-17 | 2021-05-17 | NMN formula product for prolonging chromosome telomere and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113100439A true CN113100439A (en) | 2021-07-13 |
Family
ID=76722521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110536156.1A Pending CN113100439A (en) | 2021-05-17 | 2021-05-17 | NMN formula product for prolonging chromosome telomere and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113100439A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107929133A (en) * | 2017-12-08 | 2018-04-20 | 王颖 | A kind of freckle removing and whitening SOD complex enzyme formulas |
| CN111093397A (en) * | 2017-09-14 | 2020-05-01 | 田中惠 | Anti-aging agent and anti-aging method |
| CN111329808A (en) * | 2020-04-03 | 2020-06-26 | 西安力邦医美科技有限公司 | Cosmetic composition with anti-glycosylation and anti-aging effects and application thereof |
| CN111617094A (en) * | 2019-12-30 | 2020-09-04 | 上海互众药业有限公司 | Compound preparation for delaying senility and preparation method thereof |
| CN111728211A (en) * | 2020-07-08 | 2020-10-02 | 江西邦泰绿色生物合成生态产业园发展有限公司 | Anti-aging composite preparation containing cerasus serrulata polypeptide and preparation method of anti-aging composite preparation |
| CN112089775A (en) * | 2020-10-30 | 2020-12-18 | 成都及禾生物科技有限公司 | NMN beneficial bacterium health composition and preparation method and application thereof |
| CN112155186A (en) * | 2020-11-11 | 2021-01-01 | 北京斯利安药业有限公司 | Composition for resisting oxidation and/or delaying aging, application and product thereof |
| CN112569248A (en) * | 2020-11-12 | 2021-03-30 | 深圳市旷逸生物科技有限公司 | Application of nicotinamide mononucleotide in preparing telomerase accelerant and preparation method thereof |
-
2021
- 2021-05-17 CN CN202110536156.1A patent/CN113100439A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111093397A (en) * | 2017-09-14 | 2020-05-01 | 田中惠 | Anti-aging agent and anti-aging method |
| US20200268632A1 (en) * | 2017-09-14 | 2020-08-27 | Megumi Tanaka | Anti-aging agent and anti-aging method |
| CN107929133A (en) * | 2017-12-08 | 2018-04-20 | 王颖 | A kind of freckle removing and whitening SOD complex enzyme formulas |
| CN111617094A (en) * | 2019-12-30 | 2020-09-04 | 上海互众药业有限公司 | Compound preparation for delaying senility and preparation method thereof |
| CN111329808A (en) * | 2020-04-03 | 2020-06-26 | 西安力邦医美科技有限公司 | Cosmetic composition with anti-glycosylation and anti-aging effects and application thereof |
| CN111728211A (en) * | 2020-07-08 | 2020-10-02 | 江西邦泰绿色生物合成生态产业园发展有限公司 | Anti-aging composite preparation containing cerasus serrulata polypeptide and preparation method of anti-aging composite preparation |
| CN112089775A (en) * | 2020-10-30 | 2020-12-18 | 成都及禾生物科技有限公司 | NMN beneficial bacterium health composition and preparation method and application thereof |
| CN112155186A (en) * | 2020-11-11 | 2021-01-01 | 北京斯利安药业有限公司 | Composition for resisting oxidation and/or delaying aging, application and product thereof |
| CN112569248A (en) * | 2020-11-12 | 2021-03-30 | 深圳市旷逸生物科技有限公司 | Application of nicotinamide mononucleotide in preparing telomerase accelerant and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101658537B (en) | Hypoglycemic ferment compound and its preparation method | |
| RU2615823C2 (en) | Liquid lubricant for tableting, integrated into tablets | |
| CN102125507A (en) | Oral cavity supply composition with liquoric root extract and bioadhesive function | |
| EP3385306B1 (en) | Composite particles including cellulose, inorganic compound, and hydroxypropyl cellulose | |
| AU2018361636A1 (en) | A dietary composition comprising plant-based sources of fatty acids | |
| SG185478A1 (en) | Flowable liquid composition | |
| CN115154481B (en) | A Chinese medicinal composition for preventing and treating atherosclerosis and coronary heart disease | |
| CN105031042A (en) | Medicinal composition having weight-loss function and application of medicinal composition | |
| JP2010064992A5 (en) | ||
| CN101224202A (en) | Weight reducing compound | |
| CN102743394A (en) | Composite fat-soluable vitamin injection | |
| CN113100439A (en) | NMN formula product for prolonging chromosome telomere and preparation method thereof | |
| KR20170099539A (en) | Sedum composition promoting antioxidant and alcohol oxidation | |
| CN106266252A (en) | A kind of lycopene Oleum Camelliae soft capsule and preparation method thereof | |
| CN112156076A (en) | Fat-soluble vitamin solid particles and preparation method thereof | |
| CN112335812A (en) | Tablet for supplementing vitamin K2 for adults | |
| CN110300594B (en) | Pharmaceutical composition for controlling blood sugar | |
| CN112076172A (en) | Sulcardine sulfate tablet and preparation method thereof | |
| CN101375857B (en) | Application of yew polysaccharide in preparing medicament for myocardial ischemia-reperfusion injury | |
| CN104382950B (en) | A kind of Spirulin composition and preparation method thereof, preparation | |
| CN108391762A (en) | A kind of novel duck feed and preparation method thereof containing Chinese medicine additive | |
| CN110584114B (en) | Lycopene soft capsule and preparation method thereof | |
| CN112156077B (en) | N-acetylglucosamine tablet and preparation method thereof | |
| CN117180168B (en) | Freckle-removing whitening product and preparation method and application thereof | |
| KR20240001370A (en) | Composition for promoting hair growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210713 |